Maple syrup urine disease (MSUD) results from a deficiency of branched chain a-ketoacid dehydrogenase (BCKDH). We have studied the etiology of MSUD by determining the enzyme activity, protein, and mRNA levels of BCKDH in fibroblasts from a classic MSUD patient and his parents. By enzymatic amplification of the patient's mRNA followed by cloning and DNA sequencing, we have identified a T to A transversion that alters a tyrosine to an asparagine at residue 394 of the Ela subunit. Amplification of both mRNA and genomic DNA, in combination with allele-specific oligonucleotide hybridization, demonstrated that the father was heterozygous for this mutant allele. The mother was homozygous for the allele encoding the normal Tyr394, but expressed only about half of the normal level of mRNA and protein. The patient was genetically heterozygous for this altered allele, although only the abnormal allele was expressed as mRNA. We conclude that the patient was a compound heterozygote, inheriting an allele encoding an abnormal Ela from the father, and an allele from the mother containing a cis-acting defect in regulation which abolished the expression of one of the Ela alleles. Our results revealed for the first time that a case of MSUD was caused by structural and regulatory mutations involving the Ela subunit.
Introduction
Branched chain a-ketoacid dehydrogenase (BCKDH)' catalyzes the rate-limiting step in the catabolism of the branched chain amino acids (1, 2) . Covalent modification via phosphorylation by a specific kinase and dephosphorylation by a specific phosphatase has been established as an important mechanism for regulation of BCKDH activity (3) (4) (5) . The enzyme 1. Abbreviations used in this paper: BCKDH, branched chain a-ketoacid dehydrogenase; E 1, decarboxylase component ofBCKDH; Ela, a subunit ofE1; EIfl, fi subunit ofE1; E2, acyl-transferase component of BCKDH; E3, dihydrolipoyl dehydrogenase; KIV, a-keto-isovaleric acid; MSUD, maple syrup urine disease; PCR, polymerase chain reaction. complex consists of 2-oxoisovalerate dehydrogenase (E 1, composed of Ela and Elfl, EC 1.2.4.4.) , dihydrolipoamide acyltransferase (E2, no EC number), and dihydrolipoamide dehydrogenase (E3, EC 1.8. 1.4.) . Ela is probably the catalytic subunit, and it contains the phosphorylation sites (two serine residues) responsible for regulation of the enzyme by covalent modification (6) .
Maple syrup urine disease (MSUD), inherited in an autosomal recessive fashion, is caused by a deficiency of BCKDH (7) . The disease is characterized by ketoacidosis and mental retardation, with the molecular defects most often (8) but not exclusively (9, 10) in the El component. Four clinically different forms of this disease have been described: classic, thiaminresponsive, intermediate, and intermittent (7) . To gain insight into the structure and mechanism of regulation of BCKDH complex and to define the genetic defects ofMSUD, we cloned cDNAs encoding BCKDH ElCa subunit from both rat and human liver (1 1, 12) . We report here the first determination at the DNA and RNA level of the mutations causing a case of classic MSUD: two different mutant alleles of the EI a gene. Cell strains and culture. Fibroblasts derived from a patient with classic MSUD (GM649) and his father (GM650) and mother (GM65 1) were obtained from NIGMS Human Genetic Mutant Cell Repository. Normal human fibroblast cell line was obtained from American Type Culture Collection (Rockville, MD). Fibroblasts were grown in monolayer culture in DME (Gibco, Grand Island, NY) containing 10% (vol/vol) fetal calf serum (FCS, Sigma Chemical Co., St. Louis, MO) and antibiotics (penicillin, 100 U/ml; streptomycin, 100 gg/ml) at 37°C in 5% CO2 atmosphere. The cells were grown to confluency and harvested by trypsinization 3-6 d after the last medium change.
Methods

Radioisotopes
Enzyme assay. Cells were collected by trypsinization, washed with PBS containing 10% FCS, and incubated with 1 mM a-chloroisocaprate in the culture medium at 37°C for 15 min to activate BCKDH complex by dephosphorylation. Extracts of the cells were prepared by freeze-thawing in complete Krebs-Ringer buffer. BCKDH total activity was measured radiochemically at 37°C with [1-'4C]KIV as substrate (14) .
Western blot. Crude mitochondrial pellets from the fibroblasts were prepared by treating cells with 1% digitonin (15) in buffer containing 0.25 M sucrose, 1 mM EDTA, 10 mM Tris-HCl (pH 7.5), and a spectrum of protease inhibitors (1 mM N-a-tosyl-L-lysylchloromethane, 0.1 mg/ml trypsin inhibitor from egg white, 0.5 MM each of leupeptin, aprotinin, and pepstatin A) and stored at -70'C. The frozen pellets were then resuspended in ice-cold buffer containing 30 mM KP1 (pH 7.5), 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol (DTT), 1% Triton, and the protease inhibitors as described above. The samples were sonicated three times for 10 s each with 30-s intervals on ice. A soluble fraction was obtained by centrifugation for 5 min at 14,000 g and protein concentration of the samples was determined by the bicinchoninic acid method (16) . 100 Mg of mitochondrial protein was then subjected to electrophoretic analysis on 10% polyacrylamide gels with 5% stacking gels (17) . The protein was transferred to a polyvinylidene difluoride membrane (Millipore Corp., Bedford, MA) by electroblotting. The membrane was incubated with polyclonal antibodies against El and E2 subunits of the BCKDH complex. The bound primary antibodies were then detected with the AuroProbe BLplus kit (Janssen Life Science Products, Olen, Belgium) following the manufacturer's instructions. The amounts of immunoreactive Ela, El#, and E2 proteins were quantitated with a GS300 Transmittance/Reflectance Scanning Densitometer (Hoefer Scientific Instruments, San Francisco, CA) and analyzed with an Apple IIe computer.
Northern blot. Total cellular RNA (20 Mg) prepared from fibroblasts using the guanidinium isothiocyanate method (18) was electrophoresed in a 1.5% agarose gel containing 2.2 M formaldehyde, transferred to a Hybond membrane (Amersham Corp.), and probed with nicktranslated human liver E lIa cDNA. The hybridization was carried out in 50% formamide, 50% Thomas solution A (19) , and 0.5% SDS at 42°C overnight. The blot was washed three times in 2 X SSC/0. 1% SDS at room temperature (15 min each) and 2 times in 0.2 X SSC/0.1% SDS at 60°C (30 min each) followed by autoradiography with Kodak XAR-5 film and two intensifying screens at -70°C for 48 h. The blot was scanned with an AMBIS #-scanner (Applied Microbiological Supplies, Inc., San Diego) to quantitate radioactivities associated with signals.
Polymerase chain reaction (PCR). First-strand cDNAs were generated from 30 Mg of total RNA using MMLV reverse transcriptase (Bethesda Research Laboratories) in 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 10 mM DTT, 3 mM MgC12, and 0.5 mM dNTPs (dATP, dCTP, dGTP, and dTTP) with specific antisense oligonucleotides or oligo (dT) as primers. The cDNAs were then subjected to 30-40 cycles of enzymatic amplification (20) . The five sets of sense/antisense oligonucleotides designed based on the normal human and rat cDNA se- Allele-specific oligonucleotide hybridization. The amplified cDNA and genomic DNA were slot blotted onto ZetaProbe membranes (Bio-Rad Laboratories, Richmond, CA). The allele-specific probes were: GAGCACTACCCACTG (normal), and GAGCACAACCCACTG (mutant). The probes were end-labeled using T4 polynucleotide kipase and ['y-32P]ATP. The hybridization and washing were carried out at 45 and 50°C, respectively, in the solutions described (22) . The filters were first probed with the normal allele-specific oligonucleotide. The same filters were boiled to remove the probe and then hybridized to the mutant oligonucleotide. The filters were autoradiographed at -70°C for 1-12 h.
Results
BCKDH activity andprotein level in culturedfibroblastsfrom a normal human and the MSUDfamily. As indicated in Table I , total BCKDH activity (4) in fibroblast extracts from the patient (GM649) is < 10% of normal; the father (GM650) and mother (GM65 1) each have about half of the normal activity.
Earlier kinetic studies showed that El was the component deficient in GM649 (8) . Western blots (Fig. 1) were performed to measure the protein level of BCKDH complex in the family.
The results demonstrated that the patient, mother, and father had 12%, 55%, and 59%, respectively, ofthe normal amount of immunoreactive Eta protein. The reduction in the amount of E Ca was closely paralleled by the reduction of El, in each family membser when compared to the normal control. All samples contained nearly identical amounts of E2. Measurement ofEla mRNA-leveL Northern blots of total RNA probed with human liver Ela cDNA (12) demonstrated a single mRNA band of 1.8 kb (Fig. 2) . The radioactivity of this band was quantitated and a ratio of 2.1:1.1:2.2:1.0 was obtained for normal/patient/father/mother. The higher level of BCKDH Elca mRNA in the normal control and the father than in the patient and the mother was confirmed by reprobing the filters for fl-actin mRNA to normalize the amount of total RNA loaded on the gels (data not shown). Cells were treated with a-chloroisocaprate and disrupted by freezethawing. BCKDH activity was assayed radiochemically. Each value represents the mean±SD for at least six determinations. The total activity of BCKDH of the normal fibroblasts agrees well with that reported previously (14) . Identification of Tyr to Asn mutation. To define the mutations at the DNA and RNA level, we cloned and sequenced the cDNA from the patient by reverse transcription of RNA followed by PCR to amplify specifically BCKDH Ela cDNA. Five sets of sense-antisense primers (each defining a 300-400bp region of the mRNA) were designed based on the normal human Eta cDNA sequence (12) . To obtain sequence information for the NH2-terminal 20 residues ofthe mature human protein, which had not been previously reported, PCR was performed using a sense primer based on the leader peptide sequence of the rat Ela cDNA (1 1) ( Fig. 3) . Thus, the complete coding region of the mature El a was amplified in overlapping segments and subcloned into M 13 for DNA sequencing. Only one single base substitution was found: TAC encoding tyrosine at residue 394 was changed to AAC encoding asparagine. To demonstrate that this change was not an am-0 E L.. plification or cloning artifact, four independent amplified fragments containing residue 394 were sequenced from both directions; the Tyr (TAG) to Asn (AAC) substitution was found in all cases. Allele-specific oligonucleotide hybridization. To confirm the point mutation, sequences flanking codon 394 were amplified from the RNA of the patient and his parents. Two allele-specific oligonucleotides centered at codon 394 (one containing TAC and one with AAC) were synthesized and used to probe slot blots of the amplified RNA segments. The amplified RNA from the patient hybridized only to the mutant allele-specific probe and that from the father hybridized to both probes ( Fig. 4 A) . The mother's RNA, however, hybridized only to the normal allele-specific probe, indicating that the mother expressed only the normal allele.
These allele-specific oligonucleotides were also used to probe the amplified genomic DNA segments. The DNA from the father and the mother followed the same pattern as that of the mRNA: the father was heterozygous and the mother homozygous for the normal allele ( Fig. 4 B) . However, the DNA from the patient hybridized to both probes, indicating that he was heterozygous at the gene level with regard to the point mutation, although he expressed only the'mutant mRNA.
These experiments have been replicated with three independent amplifications of RNA and genomic DNA, to rule out artifacts.
Discussion
We have studied the molecular basis for MSUD in a family with the classic form of the disease by analyzing the enzyme As shown by Western and Northern blot analysis, the mRNA level and the amount of immunoreactive El protein were each half of the normal values in-the mother, suggesting the existence of a regulatory mutation which reduced the steady state level of E Ia mRNA. In contrast, the father had a normal level of Ela mRNA, but only 59% of the normal level of Ela protein, suggesting a structural mutation which resulted in either destabilization of the El protein or inefficient translation of the E la mRNA. The patient had half of the normal ElIa mRNA level, and only 12% of the normal immunoreactive Ela protein, consistent with the hypothesis that there were different mutations in the two parents: a cis-acting regulatory mutation in the mother'that greatly reduced the expression of one ofthe Ela alleles, and a structural mutation in the father that produced an altered and unstable protein.
Since the reduction of the level of Ela mRNA correlates with the reduction in the amount of E la protein in the patient and his mother, the concomitant reduced level of E I# shown in the Western blot ( Fig. 1 (23) .
In order to define the mutations causing the disease in this family, we sequenced the cDNA from the patient encoding the entire mature protein of the El a subunit by reverse transcription of RNA followed by PCR and DNA sequencing. Only one single-base mutation (T to A) that caused a Tyr to Asn substitution at codon 394 was identified. The mutation was confirmed by allele-specific oligonucleotide hybridization of the patient's amplified RNA under the conditions which differentiate single-base mismatch (Fig. 4) . The allele-specific oligonucleotide hybridization experiment was also carried out using amplified RNA and genomic DNA from the patient's father and mother. The father's RNA and genomic DNA hybridized to both normal and mutant probes, indicating that he was heterozygous for this mutation, and expressed both the normal and mutant alleles. The mother's RNA and DNA, however, hybridized only to the normal allele-specific probe, indicating that she was homozygous normal with regard to the point mutation.
These data indicate that the affected child was a compound heterozygote. He inherited a mutant allele from his father which contained a Tyr(394) to Asn substitution. Since the father is heterozygous for this mutation and has the normal E a a mRNA level but reduced amount of El protein, we propose that this mutation affects either the translation efficiency of the mRNA or, more likely, the stability of the protein. The mother is homozygous for the normal codon 394, but expresses only half as much EIa mRNA; she must carry a cisacting mutation in one of her Ela alleles that essentially abolishes its expression as mRNA. The child inherited this nonexpressed allele (which had the normal Tyr 394) from his mother and the mutant allele (which contained Asn 394) from his father. This explains how the patient was genetically heterozygous for the Tyr to Asn substitution, yet expressed only the allele which contained the point mutation. Southern blots of genomic DNA from the members of this family probed with human E la cDNA were identical to those of the normal individuals, suggesting that there was no major gene deletion or rearrangement in either mother or patient. MSUD in this patient is thus due to two different mutant El a alleles: a cis-acting mutation which nearly eliminates expression of one allele and a point mutation which results in reduced translation efficiency and/or in an unstable El a protein.
In conclusion, our results delineate the molecular basis of MSUD in a family with the classic form of the disease at DNA and RNA level. The application of the methods established in this study should greatly facilitate the understanding of the molecular defects of this clinically heterogeneous disease.
